Analysis of pathogenesis and therapeutic effect in psoriasis

Analysis of pathogenesis and therapeutic effect in psoriasis - Analysis of pathogenesis and therapeutic effect in psoriasis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003144

Enrollment

Registered

2010-02-08

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

anti-TNFa drugs or cyclosporine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Psoriasis and inflammatory cutaneous disease patients

Exclusion criteria

Exclusion criteria: It is based on adaptation and contraindication of the drug.

Design outcomes

Primary

Measure	Time frame
Cytokine (IL-8, IL-18, IL-31, IL-33, and TNFa) and semaphorin3A in patients' serum and keratinocyte will be measured.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026